Veracyte Inc (VCYT)
35.15
+0.13
(+0.37%)
USD |
NASDAQ |
Nov 05, 10:31
Veracyte Revenue (Quarterly): 114.43M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 114.43M |
| March 31, 2024 | 96.84M |
| December 31, 2023 | 98.20M |
| September 30, 2023 | 90.11M |
| June 30, 2023 | 90.32M |
| March 31, 2023 | 82.42M |
| December 31, 2022 | 80.30M |
| September 30, 2022 | 75.59M |
| June 30, 2022 | 72.86M |
| March 31, 2022 | 67.78M |
| December 31, 2021 | 67.34M |
| September 30, 2021 | 60.37M |
| June 30, 2021 | 55.10M |
| March 31, 2021 | 36.70M |
| December 31, 2020 | 34.54M |
| September 30, 2020 | 31.12M |
| June 30, 2020 | 20.70M |
| March 31, 2020 | 31.12M |
| December 31, 2019 | 29.73M |
| September 30, 2019 | 30.97M |
| June 30, 2019 | 30.14M |
| March 31, 2019 | 29.53M |
| December 31, 2018 | 25.75M |
| September 30, 2018 | 23.47M |
| Date | Value |
|---|---|
| June 30, 2018 | 22.75M |
| March 31, 2018 | 20.04M |
| December 31, 2017 | 19.60M |
| September 30, 2017 | 17.52M |
| June 30, 2017 | 18.41M |
| March 31, 2017 | 16.43M |
| December 31, 2016 | 18.26M |
| September 30, 2016 | 18.60M |
| June 30, 2016 | 14.68M |
| March 31, 2016 | 13.55M |
| December 31, 2015 | 14.04M |
| September 30, 2015 | 12.34M |
| June 30, 2015 | 11.91M |
| March 31, 2015 | 11.22M |
| December 31, 2014 | 12.20M |
| September 30, 2014 | 9.838M |
| June 30, 2014 | 8.677M |
| March 31, 2014 | 7.476M |
| December 31, 2013 | 6.838M |
| September 30, 2013 | 5.594M |
| June 30, 2013 | 5.068M |
| March 31, 2013 | 4.384M |
| December 31, 2012 | 4.457M |
| September 30, 2012 | 3.224M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
20.70M
Minimum
Jun 2020
114.43M
Maximum
Jun 2024
65.03M
Average
67.78M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| Fonar Corp | 25.94M |
| XWELL Inc | 9.282M |
| ProPhase Labs Inc | 2.474M |
| Applied DNA Sciences Inc | 0.7975M |
| OncoCyte Corp | 0.104M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 5.734M |
| Total Expenses (Quarterly) | 109.47M |
| EPS Diluted (Quarterly) | 0.07 |
| Enterprise Value | 2.454B |
| Gross Profit Margin (Quarterly) | 68.09% |
| Profit Margin (Quarterly) | 5.01% |
| Earnings Yield | -2.13% |
| Operating Earnings Yield | 0.08% |
| Normalized Earnings Yield | 0.4035 |